Singleton DC - Search Results

1

Therapeutic targeting of the hypoxic tumour microenvironment.

Singleton DC, Macann A, Wilson WR. Singleton DC, et al. Nat Rev Clin Oncol. 2021 Dec;18(12):751-772. doi: 10.1038/s41571-021-00539-4. Epub 2021 Jul 29. Nat Rev Clin Oncol. 2021. PMID: 34326502 Review.

2

The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).

Singleton DC, Li D, Bai SY, Syddall SP, Smaill JB, Shen Y, Denny WA, Wilson WR, Patterson AV. Singleton DC, et al. Cancer Gene Ther. 2007 Dec;14(12):953-67. doi: 10.1038/sj.cgt.7701088. Epub 2007 Nov 2. Cancer Gene Ther. 2007. PMID: 17975564

3

Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer.

Lee TW, Lai A, Harms JK, Singleton DC, Dickson BD, Macann AMJ, Hay MP, Jamieson SMF. Lee TW, et al. Among authors: singleton dc. Cancers (Basel). 2020 Dec 12;12(12):3743. doi: 10.3390/cancers12123743. Cancers (Basel). 2020. PMID: 33322840 Free PMC article. Review.

4

Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411^NTR leading to therapeutic benefit.

Singleton DC, Mowday AM, Guise CP, Syddall SP, Bai SY, Li D, Ashoorzadeh A, Smaill JB, Wilson WR, Patterson AV. Singleton DC, et al. Cancer Gene Ther. 2022 Jul;29(7):1021-1032. doi: 10.1038/s41417-021-00409-2. Epub 2021 Nov 26. Cancer Gene Ther. 2022. PMID: 34837065

5

Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models.

Lee TW, Singleton DC, Harms JK, Lu M, McManaway SP, Lai A, Tercel M, Pruijn FB, Macann AMJ, Hunter FW, Wilson WR, Jamieson SMF. Lee TW, et al. Among authors: singleton dc. Mol Oncol. 2024 Mar 1. doi: 10.1002/1878-0261.13620. Online ahead of print. Mol Oncol. 2024. PMID: 38426642 Free article.

6

Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.

Singleton DC, Dechaume AL, Murray PM, Katt WP, Baguley BC, Leung EY. Singleton DC, et al. BMC Cancer. 2020 May 25;20(1):470. doi: 10.1186/s12885-020-06885-3. BMC Cancer. 2020. PMID: 32450839 Free PMC article.

7

Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G, Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D. Pettersen EO, et al. Among authors: singleton dc. J Enzyme Inhib Med Chem. 2015;30(5):689-721. doi: 10.3109/14756366.2014.966704. Epub 2014 Oct 27. J Enzyme Inhib Med Chem. 2015. PMID: 25347767 Review.

8

Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations.

Leung EY, Askarian-Amiri ME, Singleton DC, Ferraro-Peyret C, Joseph WR, Finlay GJ, Broom RJ, Kakadia PM, Bohlander SK, Marshall E, Baguley BC. Leung EY, et al. Among authors: singleton dc. Front Oncol. 2018 Oct 12;8:425. doi: 10.3389/fonc.2018.00425. eCollection 2018. Front Oncol. 2018. PMID: 30370249 Free PMC article.

9

Hypoxia-Activated Prodrugs of PERK Inhibitors.

Liew LP, Singleton DC, Wong WW, Cheng GJ, Jamieson SMF, Hay MP. Liew LP, et al. Among authors: singleton dc. Chem Asian J. 2019 Apr 15;14(8):1238-1248. doi: 10.1002/asia.201801826. Epub 2019 Jan 29. Chem Asian J. 2019. PMID: 30615821

10

In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy.

Cheng GJ, Leung EY, Singleton DC. Cheng GJ, et al. Among authors: singleton dc. Explor Target Antitumor Ther. 2022;3(3):297-320. doi: 10.37349/etat.2022.00084. Epub 2022 Jun 1. Explor Target Antitumor Ther. 2022. PMID: 36045910 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page